Shortened isoforms of the androgen receptor are regulated by the cytoprotective heat-shock protein HSPB1 and the tumor-suppressive microRNA miR-1 in prostate cancer cells

Anticancer Research

Volumn 33, Issue 11, 2013, Pages 4921-4926

  Stope, Matthias B ^a   Bradl, Juliane ^a   Peters, Stefanie ^a   Streitbörger, Andreas ^a   Weiss, Martin ^a   Zimmermann, Uwe ^a   Walther, Reinhard ^a   Lillig, Christopher H ^a   Burchardt, Martin ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

Androgen receptor; Heat shock protein HSPB1; Isoform; microRNA miR 1

Indexed keywords

ANDROGEN RECEPTOR; HEAT SHOCK PROTEIN 27; MICRORNA 1; PLASMID DNA; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CELL PROTECTION; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANDROGEN RECEPTOR; HEAT-SHOCK PROTEIN HSPB1; ISOFORM; MICRORNA MIR-1;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84891348411     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KAT and Dehm SM: Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73: 483-489, 2013.
2. Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP and Gao AC: NF- B2/p52 induces resistance to enzalutamide in prostate cancer: Role of androgen receptor and its variants. Mol Cancer Ther 12: 1629-1637, 2013.
3. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS and Luo J: Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69: 16-22, 2009.
4. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL and Tindall DJ: Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68: 5469-5477, 2008.
5. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS and Plymate SR: Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120: 2715-2730, 2010.
6. Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung H and Mudryj M: Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 67: 9001-9005, 2007.
7. Lim J, Ghadessy FJ and Yong E: A novel splice site mutation in the androgen receptor gene results in exon skipping and a non-functional truncated protein. Mol Cell Endocrinol 131: 205-210, 1997.
8. Streicher W, Zengerling F, Laschak M, Weidemann W, Höpfner M, Schrader AJ, Jentzmik F, Schrader M and Cronauer MV: AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells. World J Urol 30: 333-339, 2012.
9. Lamoureux F, Thomas C, Yin M, Kuruma H, Beraldi E, Fazli L, Zoubeidi A and Gleave ME: Clusterin inhibition using OGX-011 synergistically enhances HSP90 inhibitor activity by suppressing the heat-shock response in castrate-resistant prostate cancer. Cancer Res 71: 5838-5849, 2011.
10. Lamoureux F, Thomas C, Yin M, Kuruma H, Fazli L, Gleave ME and Zoubeidi A: A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res 17: 2301-2313, 2011.
11. Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T, Tilley WD and Butler LM: Evidence for efficacy of new HSP90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res 18: 3562-3570, 2012.
12. Leon JT de, Iwai A, Feau C, Garcia Y, Balsiger HA, Storer CL, Suro RM, Garza KM, Lee S, Sang Kim Y, Chen Y, Ning Y, Riggs DL, Fletterick RJ, Guy RK, Trepel JB, Neckers LM and Cox MB: Targeting the regulation of androgen receptor signaling by the heat-shock protein 90 co-chaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci USA 108: 11878-11883, 2011.
13. Baylot V, Katsogiannou M, Andrieu C, Taieb D, Acunzo J, Giusiano S, Fazli L, Gleave M, Garrido C and Rocchi P: Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer. Mol Ther 20: 2244-2256, 2012.
14. Stope MB, Schubert T, Staar D, Rönnau C, Streitbörger A, Kroeger N, Kubisch C, Zimmermann U, Walther R and Burchardt M: Effect of the heat-shock protein HSP27 on androgen receptor expression and function in prostate cancer cells. World J Urol 30: 327-331, 2012.
15. Stope MB, Weiss M, Stender C, Preuß M, Peters S, Schubert T, Streitbörger A, Rönnau C, Ziegler P, Ritter CA, Kroeger N, Zimmermann U, Walther R and Burchardt M: Chemoresistance in prostate cancer is initiated by phosphorylation of the heat shock protein HSP27 and subsequent suppression of microRNA miR-1: Under review, 2013.
16. Sramkoski RM, Pretlow, T G 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D and Jacobberger JW: A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35: 403-409, 1999.
17. Tepper CG, Boucher DL, Ryan PE, Ma A, Xia L, Lee L, Pretlow TG and Kung H: Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62: 6606-6614, 2002.
18. Tilley WD, Wilson CM, Marcelli M and McPhaul MJ: Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 50: 5382-5386, 1990.
19. Ischia J, Saad F and Gleave M: The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer. Curr Opin Urol 23: 194-200, 2013.
20. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K and Gleave M: Heat-shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64: 6595-6602, 2004.
21. Myung J, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ and Sadar MD: An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest 123: 2948-2960, 2013.